Abstract
Background: Hemangioma is the most prevalent infantile vascular tumor. The state of inflammation and metabolism may contribute to the occurrence and development of hemangioma, but their causal relationships have not been clearly elucidated. In this study, via Mendelian randomization (MR) analysis, we aimed to investigate the causal effect of inflammatory cytokines and blood metabolites on hemangioma, and to explore the potential mediating role of metabolites.
Methods: Applying large-scale genome-wide association studies (GWAS) dataset, we applied two-sample MR to infer causal relationships among 91 inflammatory cytokines, 1091 blood metabolites and 309 metabolite ratios，and hemangioma. In addition, a two-step MR was used to assess the potential mediating role of metabolites. Functional enrichment was also performed to explore the biological pathways involved.
Results: 9 cytokines exhibited significant causal effects on hemangioma. Cytokines such as CCL20, IFN-γ, Eotaxin and TRANCE were associated with an increased risk, while IL12B, CXCL11, TGF-α, OSM and IL17A were inversely associated. Additionally, 52 blood metabolites and metabolite-ratios were discovered to have causal effects on hemangioma. 18 metabolites and metabolite-ratios were associated with an elevated risk of hemangioma, whereas 34 metabolites and metabolite-ratios appeared to be protective factors. Mediation analysis further identified specific metabolites, such as Gamma-glutamylvaline, as mediators in cytokine-hemangioma pathways, suggesting that they might modulate cytokine-driven tumorigenesis.
Conclusion: As the first MR study focused on hemangioma, we identified key cytokines and metabolites which might exert a causal effect on hemangioma, with several metabolites functioning as intermediators in cytokine-induced tumorigenesis process. The complex interaction between inflammation and metabolism in hemangioma was revealed, laying a foundation for future studies to explore potential targeted treatments.
Keywords
Array
Array
Array
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.